vorinostat has been researched along with Atherogenesis in 2 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, Y | 1 |
| Xu, S | 1 |
| Liu, P | 1 |
| Koroleva, M | 1 |
| Zhang, S | 1 |
| Si, S | 1 |
| Jin, ZG | 1 |
| Chen, X | 1 |
| Wang, L | 1 |
| Du, Y | 1 |
| Wu, Y | 1 |
| Jia, X | 1 |
| Yang, Y | 1 |
| Hong, B | 1 |
2 other studies available for vorinostat and Atherogenesis
| Article | Year |
|---|---|
Suberanilohydroxamic Acid as a Pharmacological Kruppel-Like Factor 2 Activator That Represses Vascular Inflammation and Atherosclerosis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Atherosclerosis; Cell Adhesion; Chlorocebus | 2017 |
Design, synthesis and biological evaluation of hydroxamic acid derivatives as potential high density lipoprotein (HDL) receptor CLA-1 up-regulating agents.
Topics: Animals; Atherosclerosis; Dose-Response Relationship, Drug; Hep G2 Cells; Histone Deacetylase Inhibi | 2011 |